Microarray technology and its effect on breast cancer (re)classification and prediction of outcome by Cardoso, Fatima
303
Available online http://breast-cancer-research.com/content/5/6/303
Introduction
With screening mammography becoming more widely
used throughout Europe, a growing proportion of women
diagnosed with breast cancer present with earlier disease
stages. Although these women can enjoy long-term sur-
vival, 20%–30% will relapse and die from their disease.
There is, however, a great deal of controversy related to
the optimal definition of a low/minimal versus a moder-
ate/high risk of relapse for women with node negative
breast cancer. Many oncologists rely on the guidelines
issued by experts following consensus conferences [1].
Consequently, only 15% to 20% of patients are assigned
to a “low/minimal risk” subset and this may result in many
women with early breast cancer being over-treated – a
phenomenon that not only exposes these women to
unnecessary toxicity, but also increases the economic
burden of this frequent disease on society.
Gene expression profiles
Microarray technology is fundamentally changing our
understanding of cancer biology at the molecular level. Use
of microarrays for genome-wide expression profiling pro-
vides a more refined molecular classification of human
cancers and has reinforced the notion that breast cancer is
a heterogeneous disease. This knowledge has great poten-
tial for a better selection of patients in need of adjuvant
therapy as well as for tailored treatment approaches [2].
A landmark study in this area is the work of Sorlie and col-
leagues [3] that proposed a new classification of breast
cancer clearly separating endocrine non-responsive from
endocrine-responsive disease. Recently, Sorlie and co-
workers have confirmed their results in an independent set
of breast tumors, refining previously defined sub-types of
breast tumors that could be distinguished by their distinct
patterns of gene expression [4]. Other landmark studies
[5,6], with potentially huge implications for clinical manage-
ment of breast cancer, describe the work of the Amsterdam
group. These investigators identified a 70-gene poor-prog-
nosis signature that can accurately predict relapse-free sur-
vival in both node-negative and node-positive breast cancer.
Interestingly, the number of low-risk patients who can be
spared adjuvant chemotherapy appears to be markedly
increased (about 30%) when the prognosis-genetic signa-
ture is used instead of the commonly used consensus
guidelines. Although impressive and interesting, this work
has some weakness, such as the retrospective nature of the
study, the small sample size, and the fact that only young
women were selected (all <52) all of whom were treated in
one hospital. This makes extrapolations to other age groups
and other regions difficult [7]. It also has to be born in mind,
that microarray is a new and expensive technology that,
although evolving rapidly, needs to be fully standardized in
order to be reproducible across different laboratories.
Therefore, these interesting results needed to be dupli-
cated in an independently run study and then validated in
a large, independent, prospective trial, before being
applicable in clinical practice [8]. This has recently been
done by Sotiriou and colleagues [9] who analyzed RNAs
from an independent set of 99 breast cancer patients with
known clinical outcome. The results concur with those of
the earlier studies, despite differences in patient popula-
tions, treatments used and technology platforms
employed. This study found that the ER status of the
tumor was, indeed, the most important discriminator of
expression subtypes, confirming that ER biology plays a
central role in breast carcinogenesis. Tumor grade was
found to play a secondary role. Unsupervised hierarchical
clustering analysis segregated these 99 tumors into two
main clusters based on their basal (predominantly ER neg-
ative) and luminal (predominantly ER positive) characteris-
tics; within each of these clusters smaller subgroups were
identified, characterized by distinct gene expression signa-
tures involving different oncogene-specific pathways. As
in earlier studies, the molecular signature subgroups
showed expected differences in survival, with a better
outcome in the luminal group. In addition, the authors
identified a group of 485 different probe elements statisti-
cally associated with survival (P<0.05). Other clinical fea-
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tures, such as lymph node positivity, menopausal status,
and tumor size, were not strongly reflected in the expres-
sion patterns obtained in this investigation. Thus, the evi-
dence to date suggests that molecular profiling can
substantially refine cancer prognosis, perhaps well beyond
what is possible with other clinical indicators.
Another preliminary, but important, finding of this study is
that molecular signatures might be generalized to popula-
tions other than those in which they were initially devel-
oped, and across multiple microarray platforms and
technologies. Sotiriou and colleagues found substantial
evidence that the 231 expressed genes reported as sepa-
rating survival groups in the Van’t Veer study [5] have
prognostic relevance in a different, heterogeneous popula-
tion of node positive and node negative patients treated
with adjuvant therapy.
Conclusions and future directions
Given the high potential of gene expression profiling to
change clinical practice, it is now important to validate
this new prognostic tool in a large, independent and
prospective trial. Such a study - the MINDACT trial – is
already in an advanced stage of preparation and will be
run through the Breast International Group network, coor-
dinated by the European Organization for Research and
Treatment of Cancer (EORTC), and funded by the Euro-
pean Commission under the Framework VI Programme.
MINDACT will evaluate the role of the gene prognosis
signature in the selection of good prognosis versus bad
prognosis node negative breast cancer patients and aims
to identify a subgroup of these patients that can be
spared adjuvant chemotherapy.
Despite their importance, translating these outstanding
advances in basic biological knowledge into clinical bene-
fits in the prevention, diagnosis and treatment of breast
cancer has been difficult and slow.
In the present era, where we are rapidly moving from
empirical towards molecular oncology in cancer manage-
ment, only large, well-conducted, biologically-based
prospective trials will allow us to reach the needed conclu-
sions and to shorten the lapse of time for the clinical appli-
cation of new markers and techniques.
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